SavedAdd your journal

Journals / KONURALP TIP DERGİSİ / 2026 / Volume: 13 Issue: S1 Special Issue

A Case of COVID-19 in a patient with Pemphigus successfully managed with favipiravir

Abdullah Demirbaş(Kütahya Health Sciences University, Evliya Çelebi Training and Research Hospital, Department of Dermatology, Kütahya)0000-0002-3419-9084
Ömer Faruk Elmas(Kırıkkale University, Faculty of Medicine, Department of Dermatology, Kırıkkale)0000-0002-5474-6508
Mustafa Atasoy(Health Science University, Kayseri City Hospital, Department of Dermatology, Kayseri)0000-0003-1904-9878
Gözde Ulutaş Demirbaş(Akçaabat Haçkalı Baba State Hospital, Department of Dermatology, Trabzon)0000-0002-1468-4605
Ümit Türsen(Mersin University, Faculty of Medicine, Department of Dermatology, Mersin)0000-0002-5807-6759
Torello Lottı(Guglielmo Marconi University, Department of Dermatology, Rome, Italy)0000-0003-0840-1936
Asuman Kilitci(Kırşehir Ahi Evran University, Faculty of Medicine, Department of Pathology, Kırşehir)0000-0002-5489-2222
Pages
—
Publication Date
2021-08-30
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We present the case of COVID-19 that developed in a 38-year-old female patient with pemphigus successfully managed with favipiravir.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:COVID-19 is not only a respiratory disease, but a multisystem disease that can cause organ dysfunction and coagulation disorder associated with high mortality and morbidity, particularly in vulnerable populations.
📊
Key Findings & Data:Severe complications can be seen especially in elderly patients with systemic disease and immunosuppressive patients.
💡
Conclusion & Impact:We present the case of COVID-19 that developed in a 38-year-old female patient with pemphigus successfully managed with favipiravir.
🔬Design:Letter to Editor
📍Scope:Comprehensive Sample
⚙️Variables:COVID-19 · Pemphigus · Favipiravir

Abstract

COVID-19 is not only a respiratory disease, but a multisystem disease that can cause organ dysfunction and coagulation disorder associated with high mortality and morbidity, particularly in vulnerable populations. Severe complications can be seen especially in elderly patients with systemic disease and immunosuppressive patients. We present the case of COVID-19 that developed in a 38-year-old female patient with pemphigus successfully managed with favipiravir.

Özet

COVID-19 sadece bir solunum hastalığı değil, aynı zamanda özellikle hassas popülasyonda yüksek mortalite ve morbidite ile ilişkili organ disfonksiyonuna ve pıhtılaşma bozukluğuna neden olabilen multisistemik bir hastalıktır. Özellikle sistemik hastalığı olan yaşlı hastalarda ve immünsüpresif hastalarda ciddi komplikasyonlar görülebilmektedir. Favipiravir ile başarılı bir şekilde tedavi edilen pemfiguslu 38 yaşındaki bir kadın hastada gelişen COVID-19 vakasını sunuyoruz.

🔖

Cite This Article

Demirbaş, A., Elmas, Ö. F., Atasoy, M., Demirbaş, G. U., Türsen, Ü., Lottı, T., Kilitci, A. (2021). A Case of COVID-19 in a patient with Pemphigus successfully managed with favipiravir. KONURALP TIP DERGİSİ, Volume: 13 Issue: S1 Special Issue. https://doi.org/10.18521/ktd.896761

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Demirbaş A, Elmas ÖF, Türsen Ü, Atasoy M, Lotti T. Superficial thrombophlebitis in a patient with COVID 19: Heparin treatment after evaluation of D-Dimer. Dermatol Ther. 2020;33(4): e13768.
  2. Beyazçiçek Ö, Beyazçiçek E, Demir S. Are Blood Groups Protective Against COVID-19?. Konuralp Med J. 2021;13(1): 160-7.
  3. Elmas ÖF, Demirbaş A, Türsen Ü, Atasoy M, Lotti T. Pemphigus and COVID-19: Critical overview of management with a focus on treatment choice. Dermatol Ther. 2020: e14265.
  4. Shakshouk H, Daneshpazhooh M, Murrell DF, Lehman JS. Treatment considerations for patients with pemphigus during the COVID-19 pandemic. J Am Acad Dermatol. 2020;82(6): e235-e236.
  5. Schmidt E. Rituximab as first-line treatment of pemphigus. Lancet. 2017;389(10083): 1956-8.
  6. Karabay O, İnci M, Öğütlü A, Ekerbiçer H, Güçlü E, Dheir H, et al. Is it possible to predict mortality using initial data of adult patients hospitalized with COVID-19? A mortality prediction model in the early phase of COVID-19. Konuralp Med J. 2021;13(1): 36-44.
  7. Kasperkiewicz M, Schmidt E, Fairley JA, Joly P, Payne AS, Yale ML, et al. Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2020;34(7): e302-e303.
  8. Guidance from the EADV Task Force Autoimmune Blistering Diseases during the COVID-19 pandemic. The EADV Task force Autoimmune Blistering Diseases supports patients and their families during this difficult period of COVID-19 pandemic and provides the following advices. 2020.
  9. Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID-19?. J Antimicrob Chemother. 2020;75(7): 2013-4.
  10. Dheir H, Yaylacı S, Sipahi S, Şenocak D, Toptan H, Aşıcı N, et al. The effectiveness of favipiravir treatment in severe COVID-19 pneumonia: A single center experience. Konuralp Med J. 2021; 13(1): 4-10.
  11. Nasir M, Perveen RA, Saha SK, Talha KA, Selina F, Islam MA. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2. Mymensingh Med J. 2020;29(3): 747-54.